The objective of this study was to examine the effect of angiotensin II (Ang II) and angiotensin II type 1 (AT 1 ) receptor blockade on pulse wave velocity (PWV) in healthy humans. We studied nine young male volunteers in a double-blind randomised crossover design. Carotidfemoral PWV (an index of arterial stiffness) was measured by using a Complior  machine. Subjects were previously treated for 3 days with once-daily dose of either a placebo or valsartan 80 mg. On the third day, they were infused with either placebo or 5 ng/kg/min of Ang II over 30 min. Subjects thus received placebo capsule + placebo infusion (P), valsartan + placebo infusion (V), placebo + Ang II infusion (A), and valsartan + Ang II infusion (VA) combinations. Heart rate (HR), blood pressure and PWV were recorded at baseline and then every 10 min during infusion and once after the end of infusion. There were significant increases in systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) with A compared with
Introduction
The angiotensin-converting enzyme (ACE) inhibitors have been shown to increase arterial compliance in patients with hypertension 1 as well as in normotensive subjects. 2 This forms an indirect evidence for the role of angiotensin II (Ang II) in arterial stiffness. The local vascular renin angiotensin system (RAS) is an important autocrine or paracrine system responsible for the control of large artery structure. Studies have shown that Ang II, the main effector hormone of the RAS, is responsible for the growth and hypertrophy of vascular smooth muscle cells, 3, 4 proliferation of endothelial cells, production and accumulation of collagen and stimulation of P (P = 0.002, P = 0.002, P = 0.001 respectively). These rises in blood pressure were completely blocked by valsartan. A significant rise in PWV by A was seen compared with P (8.38 ± 0.24 vs 7.48 ± 0.24 m/sec, P = 0.013) and was completely blocked by valsartan; VA compared with P (7.27 ± 0.24 vs 7.48 ± 0.24 m/sec, P = NS). Multiple linear regression analysis showed that blockade of Ang II induced increase in blood pressure by valsartan contributed to only 30% of the total reduction in Ang II induced rise in PWV (R 2 hormones like endothelin in the vessel wall. Ang II through these actions may also contribute to increased stiffness and all these effects are mediated through Ang II type 1 (AT 1 ) receptors. AT 1 receptor gene polymorphism has been shown related to arterial stiffness in hypertensive patients 5 supporting a role of Ang II in arteriosclerosis mediated via AT 1 receptors.
We have already shown in another clinical study that Ang II increases pulse wave velocity (PWV), an indirect measure of arterial stiffness, when infused in 5 ng/kg/min dose in normal human volunteers. 6 The present study was done to see if the effect of Ang II on arterial stiffness measured as PWV was mediated through AT 1 receptors.
Methods
A double-blind, randomised, crossover, placebocontrolled study was designed and approved by the Research and Ethics committee, School of Medical Sciences, Universiti Sains Malaysia. Nine healthy male volunteers were recruited (mean age 24.7 ± 0.66 years) after informed written consent. Complete history, general physical and systemic examinations, haematological and biochemical screens were done to exclude any cardiovascular, renal or hepatic disease. Subjects with factors which make measurement of PWV difficult such as body mass index (BMI) Ͼ35 kg/m 2 and haematocrit Ͻ35% or Ͼ55% were also excluded.
Volunteers receiving four different treatment combinations were studied on four different study days under standardised conditions after a washout period of at least 1 week. Consumption of alcohol, medication (prescribed or over the counter), vitamins, herbal remedies, caffeine and smoking were not allowed for 24 h before the start of clinical study. Added salt in the food and strenuous activity were also avoided. Volunteers were treated with once-daily dose of valsartan 80 mg (Diovan  ; Novartis Pharma AG, Basel, Switzerland) or a placebo for 3 days. On the third day fasting volunteers reported to the clinical trial unit, where intravenous line (i.v.) was placed in their left forearm and allowed to rest for 10 min in supine position for reattainment of basal conditions. After the baseline measurements for heart rate (HR), blood pressure (BP) and PWV, a 30-min continuous i.v. infusion (Terumo, Terfusor syringe/infusion pump, TE-311, Japan) of either Ang II (5 ng/kg/min) or a placebo was started. Ang II has a pressor effect at this dose 7, 8 and has been shown to increase PWV in normal healthy volunteers. 6 HR, BP and PWV were measured every 10 min during infusion and once after the end of infusion. In this way each volunteer received four treatment combinations, namely, placebo capsule + placebo infusion (P), valsartan + placebo infusion (V), placebo + Ang II infusion (A), and valsartan + Ang II infusion (VA).
Carotid-femoral PWV was measured to assess aortic stiffness using the Complior  machine (Colson, France). The Complior  has been validated for measurement of PWV and has been used in other clinical studies.
9-11 The observer's technique for the use of Complior  was validated by the validation centre Institut de Recherche et Formation Cardiovasculaire, France, and repeatability of measurements assessed as the intraday and interday coefficient of variation of 1.5% and 4.06% respectively. Systolic and diastolic blood pressures were measured in duplicate using a mercury column sphygmomanometer (Tycos  , USA) and pulse pressure (PP) and mean arterial pressure (MAP) were then calculated using the standard formulae. Heart rate was counted manually using a stopwatch. Mean of beats counted for 1 min were recorded. All measurements were done by the same person on the right side of the volunteers throughout the study, opposite to the infusion arm.
Sample size was calculated before starting the study, based on the results from a previous study. 6 Number of subjects needed to detect a difference in the mean PWV of 3 m/sec 10 with a standard deviation of 1.4 at the power of 80% and alpha of 0.05 12, 13 is eight. Data were analysed using SPSS package version 9.0 (Chicago, Illinois, USA). Repeated measures analysis of variance was used to detect the overall effect of the treatment over time.
Stepwise multiple linear regression analysis was used to evaluate the predictors of the change in PWV with Ang II and AT 1 receptor blockade. All data including those in the figures and tables are expressed as mean ± standard error of the mean and P Ͻ 0.05 was considered significant.
Results
There was no significant difference in the baseline HR, BP and PWV on four study days (Table 1) . A significant increase in SBP ( Figure 1 ) DBP ( Figure 2 ) and MAP ( Figure 3 ) was seen when Ang II was infused on placebo (ie treatment A vs P: 121.68 ± 2.26 vs 111.00 ± 2.26 mm Hg, P = 0.002; 81.22 ± 3.22 vs 66.22 ± 3.22 mm Hg, P = 0.002 and 94.85 ± 2.51 vs 81.23 ± 2.51 mm Hg, P = 0.001). Significant rises in BP by Ang II infusion on placebo, were accompanied by a significant increase in PWV (Figure 4 ) (ie treatment A vs P; 8.37 ± 0.24 vs 7.48 ± 0.24 m/sec, P = 0.013). However these rises in BP were completely blocked by prior treatment with valsartan (Figures 1-3 ; as seen by treatment P vs VA = NS). Similarly an increase in PWV caused by Ang II infusion on placebo was also completely blocked when Ang II was infused after prior treatment with valsartan (ie treatment A vs VA; 8.37 ± 0.24 vs 7.27 ± 0.24 m/sec, P = 0.003, Figure 4) . No significant difference in effect on PWV was seen when placebo was infused on valsartan compared with placebo infusion on placebo (ie treatment V vs P; 7.27 ± 0.24 vs 7.48 ± 0.24 m/sec, P = 0.557, Figure 4) . No significant change was seen in PP and HR by any of the treatment combinations used in this study.
Change in PWV contributed by change in BP (Tables 2 and 3)
Results from multiple linear regression analysis showed that when treatment combination A was compared with P, change in PWV could not be fully explained by changes in BP. Change in BP (systolic BP (SBP) and MAP) explained only 55% (P = 0.010 and P = 0.021) of the total increase in PWV (R 2 = 0.554; Table 2 ). Similarly when treatment combination A was compared with VA, absolute fall in Ang II induced rise in PWV could not be fully explained by blockade of Ang II induced rises in BP (SBP, diastolic BP (DBP) and MAP). In addition blockade of Ang II induced rise in BP (MAP, P Ͻ 0.001) explained only 30% of the absolute change (total reduction/prevention) in Ang II induced rise in PWV (R 2 = 0.306) by valsartan (Table 3) . No significant difference was seen in the baseline parameters on four clinical sessions using different treatment combinations after 3 days treatment with either placebo or valsartan.
Figure 1 Effect of different treatment combinations on SBP.
Treatment A is significantly different from P*, while VA is not different from P (P = 0.519).
Figure 2 Effect of different treatment combinations on DBP.
Treatment A is significantly different from P*, while VA is not different from P (P = 0.455).
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Figure 3 Effect of different treatment combinations on MAP.
Treatment A is significantly different from P*, while VA is not different from P (P = 0.412).
Figure 4 Effect of different treatment combinations on PWV.
Treatment A is significantly different from P*, while VA is not different from P (P = 0.557). Ang II induced rises in SBP and MAP correlated significantly to the change in PWV. Treatment combination A = placebo capsule and Ang II infusion, and P = placebo and placebo infusion. 
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Discussion
We have already shown in a previous study that Ang II increases PWV when given in a dose of 5 ng/kg/min. We also showed that Ang II induced rise in PWV could not be fully explained by Ang II induced rise in BP only and was probably due to a combination of its pressor and non-pressor effects. 6 This study was done to see if the effect of Ang II on PWV was mediated solely by AT 1 receptors and is the first one to investigate the effect of prior blockade of AT 1 receptors on Ang II induced rise in PWV in humans. Healthy male volunteers were chosen to exclude the confounding effects of age, gender and disease states. Results from the study showed that Ang II, at the given dose, increased BP (SBP, DBP and MAP) and PWV significantly. Rises in BP were similar to those seen in our previous study, 6 and to those reported by others, using different doses of Ang II infusion to see its effect on BP and other parameters. 7, 8, 14 Increase in BP was in the range of 15-20 mm Hg systolic and diastolic. Complete blockade of Ang II induced rises in BP and PWV by 3 days treatment with valsartan suggested that the effect of Ang II on BP and PWV is mediated via AT 1 receptors.
The study has also shown that treatment of normal volunteers with valsartan only, did not affect BP and PWV under standardised conditions, which is in contrast to that reported by Muller et al. 15 They treated 16 healthy volunteers with valsartan (200 mg) for 8 days and showed a significant fall in SBP and DBP. The difference in effect of valsartan between the two studies could reflect a different salt intake by the respective volunteers, however racial differences in response to the drug 16 cannot yet be excluded. Results from the two studies showed no change in HR. Complete blockade of pressor effect of Ang II by prior AT 1 antagonism in healthy volunteers has also been reported in other clinical studies done by Shiels et al 17 and Morgan et al. 18 Besides the effect on BP, our study also showed that valsartan completely blocked the effect of Ang II on PWV. In the past a study comparing effects of AT 1 receptor blockade (losartan) and ACE inhibition (enalapril) on aortic compliance with similar results, was reported in dogs by Barra et al. 19 Multiple linear regression analysis of the data from the present study however suggested that not all of the Ang II induced rise in PWV could be explained by the Ang II induced rise in BP. Moreover not all the reduction in Ang II induced rise in PWV was due to prevention of Ang II induced rise in BP by valsartan. The data suggested a significant correlation between absolute changes in PWV and SBP and MAP while a non-significant correlation between change in PWV and DBP. This differential correlation between BP parameters and PWV has already been reported in a previous study 11 both in the case of normotensive volunteers and hypertensive patients. On the other hand, the significant correlation between absolute changes in PWV and MAP only, as seen in treatment combination A vs VA might have resulted from the drug's effect. This partial pressure independent effect of Ang II on PWV can be explained by direct effects of Ang II like smooth muscle activation, stimulation of vasoactive substances in the vessel wall like endothelin and down regulation of bradykinin pathway. The analysis of the data also showed that less than 30% of the total effect of valsartan on PWV could be explained by the effect of valsartan on BP. The rest was probably due to an independent effect of the drug on arterial wall which includes not only blockade of the effects of Ang II mediated through AT 1 but also enhancing those mediated via AT 2 (Ang II type 2 receptors).
The effects of Ang II mediated through AT 2 receptors are suggested to be opposite to the ones mediated through AT 1 . These include growth inhibition, antiproliferation, cell differentiation and apotosis. 20 AT 2 receptor stimulation has also been shown to exert vasodilatory effects as shown in animal studies. 21, 22 This is probably due to Ang II mediated release of bradykinin through AT 2 receptors and has been shown blocked by bradykinin receptor blockade. 23 AT 2 receptors stimulation has also been shown to enhance the antihypertensive effect of AT 1 antagonists in spontaneously hypertensive rats. 24 However the role of Ang II type 2 receptors still needs to be investigated in detail in humans.
The finding of a probable pressure independent effect of a drug (such as valsartan) on arterial wall is similar to that reported by Asmar et al. 11 Asmar et al 11 studied the effect of long-term (6 months) treatment of perindopril on BP and carotid-femoral PWV in mild to moderate hypertensive patients. They showed that perindopril reduced BP and PWV in these patients and less than 10% of the total reduction in PWV could be explained by the reduction in BP. The effect of AT 1 antagonism on arterial compliance in healthy volunteers has not been reported but has been studied in hypertensive patients by Benetos et al 25 Benetos et al 25 studied the effect of irbesartan (150 mg) on wall thickness and compliance of carotid and radial arteries. They showed a differential effect of irbesartan at the site of carotid and radial artery and emphasised the importance of local vascular Ang II and therefore AT 1 blockade. Similarly, Mahmud and Feely 26 have reported the additional beneficial effect of adding valsartan (80 mg) on BP, aortic PWV and augmentation index, in patients with uncontrolled hypertension already being treated with two antihypertensive drugs (including an ACE inhibitor).
We realise certain limitations in our study. First limitation is lack of plasma levels of valsartan and hormones including Ang II, ET-1, ANP and ADH at the time of PWV measurements so as to correlate the prevailing plasma levels with the results. A concomitant rise in BP however, does show the presence of circulating Ang II in the blood. Similarly prevention in the rise in BP when Ang II was infused after prior treatment with valsartan suggests an adequate drug effect. The possible limitation of inclusion of volunteers (three out of nine) with a family history of hypertension affecting their baseline arterial stiffness 27 can be excluded by results reported by Rajzer et al. 28 Their reports suggested no significant effect of family history of hypertension on aortic stiffness in terms of PWV. In conclusion our study not only confirms the findings from our previous study that Ang II increases PWV through both its pressor and non-pressor effects, it also shows that the effect of Ang II on PWV is mediated through AT 1 receptors. This is an important point to be taken into account while treating patients with an activated renin angiotensin system (RAS), such as those with heart failure and renal failure, to allow a complete blockade of detrimental effects of this important hormone. More specific blockade of Ang II may be required since Ang II may be formed by non-ACE chymase pathway 29 as well. We suggest human studies comparing effects of ACE inhibition and AT 1 receptor blockade on PWV to further investigate the role of bradykinin and alternative pathways of Ang II formation in arterial compliance.
